Literature DB >> 10085241

Selective loss of PMA-stimulated expression of matrix metalloproteinase 1 in HaCaT keratinocytes is correlated with the inability to induce mitogen-activated protein family kinases.

B D Sudbeck1, P Baumann, G J Ryan, K Breitkopf, R Nischt, T Krieg, C Mauch.   

Abstract

Many cell types, including fibroblasts and primary keratinocytes, increase matrix metalloproteinase 1 (MMP-1) production in response to agonists such as growth factors and phorbol esters. However, the spontaneously transformed human keratinocyte cell line HaCaT, although it increases MMP-1 production in response to epidermal growth factor (EGF), does not respond similarly to stimulation with PMA. This phenomenon occurs even though HaCaT cells remain proliferatively responsive to both agonists, suggesting a HaCaT-specific defect in a PMA-mediated signal transduction pathway. Using an inside-out approach to elucidate the source of this defect, we found that EGF, but not PMA, stimulated MMP-1 promoter activity in transiently transfected HaCaT keratinocytes. In addition, an assessment of fibroblast and HaCaT c-fos and c-jun gene expression after exposure to EGF and PMA showed that although both agonists increased the expression of c-fos and c-jun mRNA in fibroblasts, only EGF did so in HaCaT keratinocytes. Finally, we looked at the activation of mitogen-activated protein (MAP) family kinases after stimulation with EGF or PMA and found that both agonists increased the phosphorylation and activation of fibroblast extracellular signal-regulated protein kinase and c-Jun N-terminal kinase, but only EGF activated the same kinase activities in HaCaT cells. Further, the EGF-mediated increase in MMP-1 gene expression was inhibited by the MAP kinase/ERK kinase (MEK)-specific inhibitor PD98059 and the p38 kinase-specific inhibitor SB203580. Our evidence indicates that although HaCaT MAP kinases are functional, they are not properly regulated in response to the activation of protein kinase C, and that the defect that bars HaCaT MMP-1 expression in response to stimulation with PMA lies before MAP kinase activation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10085241      PMCID: PMC1220141     

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  57 in total

1.  Cell-matrix interactions induce tyrosine phosphorylation of MAP kinases ERK1 and ERK2 and PLCgamma-1 in two-dimensional and three-dimensional cultures of human fibroblasts.

Authors:  O Langholz; D Roeckel; D Petersohn; E Broermann; B Eckes; T Krieg
Journal:  Exp Cell Res       Date:  1997-08-25       Impact factor: 3.905

2.  A dominant-negative mutant of raf blocks mitogen-activated protein kinase activation by growth factors and oncogenic p21ras.

Authors:  D Schaap; J van der Wal; L R Howe; C J Marshall; W J van Blitterswijk
Journal:  J Biol Chem       Date:  1993-09-25       Impact factor: 5.157

3.  Protein kinase C alpha activates RAF-1 by direct phosphorylation.

Authors:  W Kolch; G Heidecker; G Kochs; R Hummel; H Vahidi; H Mischak; G Finkenzeller; D Marmé; U R Rapp
Journal:  Nature       Date:  1993-07-15       Impact factor: 49.962

4.  Insulin activates myelin basic protein (p42 MAP) kinase by a protein kinase C-independent pathway in rat adipocytes. Dissociation from glucose transport.

Authors:  Y Yang; R V Farese
Journal:  FEBS Lett       Date:  1993-11-01       Impact factor: 4.124

5.  Mitogen-activated protein kinase activation is not sufficient for stimulation of glucose transport or glycogen synthase in 3T3-L1 adipocytes.

Authors:  L J Robinson; Z F Razzack; J C Lawrence; D E James
Journal:  J Biol Chem       Date:  1993-12-15       Impact factor: 5.157

6.  Differential Raf requirement for activation of mitogen-activated protein kinase by growth factors, phorbol esters, and calcium.

Authors:  T S Chao; D A Foster; U R Rapp; M R Rosner
Journal:  J Biol Chem       Date:  1994-03-11       Impact factor: 5.157

7.  Mitogen-activated protein kinase/extracellular signal-regulated protein kinase activation by oncogenes, serum, and 12-O-tetradecanoylphorbol-13-acetate requires Raf and is necessary for transformation.

Authors:  J Troppmair; J T Bruder; H Munoz; P A Lloyd; J Kyriakis; P Banerjee; J Avruch; U R Rapp
Journal:  J Biol Chem       Date:  1994-03-04       Impact factor: 5.157

8.  Post-transcriptional regulation of collagenase and stromelysin gene expression by epidermal growth factor and dexamethasone in cultured human fibroblasts.

Authors:  A M Delany; C E Brinckerhoff
Journal:  J Cell Biochem       Date:  1992-12       Impact factor: 4.429

9.  Activation of ternary complex factor Elk-1 by MAP kinases.

Authors:  R Janknecht; W H Ernst; V Pingoud; A Nordheim
Journal:  EMBO J       Date:  1993-12-15       Impact factor: 11.598

10.  Growth factors induce nuclear translocation of MAP kinases (p42mapk and p44mapk) but not of their activator MAP kinase kinase (p45mapkk) in fibroblasts.

Authors:  P Lenormand; C Sardet; G Pagès; G L'Allemain; A Brunet; J Pouysségur
Journal:  J Cell Biol       Date:  1993-09       Impact factor: 10.539

View more
  4 in total

1.  Myocilin regulates cell proliferation and survival.

Authors:  Myung Kuk Joe; Heung Sun Kwon; Radu Cojocaru; Stanislav I Tomarev
Journal:  J Biol Chem       Date:  2014-02-22       Impact factor: 5.157

2.  TGF-beta1 + EGF-initiated invasive potential in transformed human keratinocytes is coupled to a plasmin/MMP-10/MMP-1-dependent collagen remodeling axis: role for PAI-1.

Authors:  Cynthia E Wilkins-Port; Qunhui Ye; Joseph E Mazurkiewicz; Paul J Higgins
Journal:  Cancer Res       Date:  2009-04-21       Impact factor: 12.701

3.  Interleukin-1α Induction in Human Keratinocytes (HaCaT): An In Vitro Model for Chemoprevention in Skin.

Authors:  T Magcwebeba; S Riedel; S Swanevelder; P Bouic; P Swart; W Gelderblom
Journal:  J Skin Cancer       Date:  2012-06-25

4.  PAI-1 is a Critical Upstream Regulator of the TGF-beta1/EGF-Induced Invasive Phenotype in Mutant p53 Human Cutaneous Squamous Cell Carcinoma.

Authors:  Cynthia E Wilkins-Port; Craig E Higgins; Jennifer Freytag; Stephen P Higgins; J Andrew Carlson; Paul J Higgins
Journal:  J Biomed Biotechnol       Date:  2007-03-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.